Stay updated on Comparison of Treatments for TFE/tRCC Clinical Trial
Sign up to get notified when there's something new on the Comparison of Treatments for TFE/tRCC Clinical Trial page.

Latest updates to the Comparison of Treatments for TFE/tRCC Clinical Trial page
- Check3 days agoChange DetectedThe study record describes a phase 2 trial of axitinib and nivolumab for TFE/translocation renal cell carcinoma, including treatment arms, eligibility criteria, outcome measures, and study locations. It also shows the study is active but no longer recruiting and includes posted results and study documents.SummaryDifference100%

- Check10 days agoChange DetectedThe site footer’s revision label changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check17 days agoChange DetectedA sitewide banner announces NIH website updates and says that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during a transition.SummaryDifference1%

- Check24 days agoChange DetectedThe revision identifier in the page footer changed from v3.7.1 to v3.7.2 while the study page continued to display a 403 error.SummaryDifference0.2%

- Check31 days agoChange DetectedThe site footer revision identifier changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check52 days agoChange DetectedThe page now renders a 403 Forbidden error instead of the study content, displaying minimal navigation and an error message. This indicates restricted access to the study information.SummaryDifference17%

Stay in the know with updates to Comparison of Treatments for TFE/tRCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Comparison of Treatments for TFE/tRCC Clinical Trial page.